1. Scrip
  3. >>Deals

C4XD Inks Third Major Deal, This Time With AZ For Oral COPD Drug

Gets $2m Upfront

 
• By Ayisha Sharma

The UK firm has out-licensed its NRF2 activator programme to AstraZeneca in its third major deal of the year as it works to stabilize cash flow through a broad-ranging approach to partnerships.   

Hands holding paper lungs on blue background
COPD Is The Third Leading Cause Of Death Globally • Source: Shutterstock

C4X Discovery Holdings plc has out-licensed a its preclinical NRF2 activator programme for inflammatory and respiratory diseases to AstraZeneca PLC in a deal that could be worth up to $402m as part of an underlying diversification strategy.

Under the terms of the deal, C4XD is set to receive preclinical milestones of up to $16m, including $2m upfront

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.